How long can niraparib combined with bevacizumab last?

Niraparib (Niraparib and bevacizumab combination therapy for some patients with ovarian cancer can prolong the time to disease progression. Several clinical trials have shown that the combination of niraparib and bevacizumab has a significant effect in prolonging progression-free survival. For example, treatment regimens that combine PARP inhibitors with bevacizumab can extend progression-free survival by several months to a year in some patients with ovarian cancer. However, the exact length of time that can be extended varies from person to person and depends on the patient's condition, physical condition, and other treatment factors. If patients are receiving niraparib and bevacizumab combination therapy, it is recommended to have a detailed consultation with their doctor to understand the possible expected effects and risks of this treatment regimen.